###begin article-title 0
###xml 22 39 <span type="species:ncbi:10407">hepatitis B virus</span>
Molecular analysis of hepatitis B virus "a" determinant in asymptomatic and symptomatic Mexican carriers
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 70 71 70 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 73 74 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 76 78 76 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X </italic>
###xml 82 83 82 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 89 91 89 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S </italic>
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
###xml 19 22 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 369 372 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Hepatitis B virus (HBV) is a small DNA-containing virus with 4 genes, C, S, X and P. The S gene codes for the surface antigen (HBsAg), which contains the "a" determinant, the main region for induction of a protective humoral immune response. To compare the genotype and sequence of the "a" determinant between strains isolated from asymptomatic and symptomatic Mexican HBV carriers.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 269 271 269 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S </italic>
###xml 427 429 427 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 477 479 477 479 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 743 745 743 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S </italic>
###xml 110 113 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
###xml 619 627 <span type="species:ncbi:9606">patients</span>
21 asymptomatic (blood donors) and 12 symptomatic (with clinical signs and with >1 year lamivudine treatment) HBV carriers were studied; all patients were positive for the HBsAg in serum. Viral load, genotypes, and subtypes were determined in plasma. A fragment of the S gene including the "a" determinant was PCR amplified and sequenced to determine genotype, subtype and to identify mutations. Mean viral load was 0.7965 x 104 copies/ml in asymptomatic carriers and 2.73 x 106 copies/ml in symptomatic patients. Genotypes H, C, and F were identified in asymptomatic individuals; whereas H was dominant in symptomatic patients. A fragment of 279 bp containing the "a" determinant was amplified from all 33 carriers and sequences aligned with S gene sequences in the GenBank. Mutations identified were Y100N, T126I, Q129H and N146K in the asymptomatic group, and F93I and A128V in the symptomatic group.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 125 128 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Differences in genotype and in mutations in the "a" determinant were found between strains from asymptomatic and symptomatic HBV Mexican carriers.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 173 179 173 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PreS/S</italic>
###xml 181 187 181 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PreC/C</italic>
###xml 189 190 189 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 196 197 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 203 211 203 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pre S/S </italic>
###xml 296 303 296 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PreC/C </italic>
###xml 360 362 360 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X </italic>
###xml 417 419 417 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 501 502 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 598 599 598 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 600 601 600 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 717 718 717 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 895 896 895 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 897 898 897 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 899 901 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 902 904 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 946 948 946 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 949 951 949 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1048 1050 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
###xml 19 22 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 974 982 <span type="species:ncbi:9606">patients</span>
Hepatitis B virus (HBV) is a small, non-cytopathic virus with a circular partially double-strand DNA genome of approximately 3.2 Kb [1]. The genome has 4 overlapping genes: PreS/S, PreC/C, X, and P. The Pre S/S gene encodes for the three envelope proteins, large, middle, and small or HBsAg. The PreC/C gene encodes for the nucleocapsid protein and HBeAg. The X gene encodes for the transactivating protein X and the P gene encodes for polymerase with reverse transcriptase (RT) and RNase H activity [1]. The HBsAg contains the major epitopes for induction of a protective humoral immune response [2-6]. These epitopes are localized in the region known as the "a" determinant, between amino acid residues 99 and 169 [7-10], and are involved in the binding of antibodies against HBsAg. Amino acids changes in this region render mutant strains able to escape immune responses induced by vaccines [5,6,11,12]. Immune-escape mutants occur naturally [13-15], and in strains from patients with a weak or negative HBsAg reactivity in detection assays [10,15].
###end p 9
###begin p 10
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 0 3 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 354 357 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 408 411 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
HBV strains are classified into 8 main genomic groups or genotypes, designated A through H [16-18], arbitrarily defined by an intergroup divergence of more than 8% based on the complete genomes [16,19-21]. The relationship between subtypes and genotypes has been reported, and several studies have described the geographic distribution for the different HBV subtypes/genotypes [16,17,20,22-25]. The study of HBV genotype has recently been focused on the clinical outcome of the infection, since studies suggest a possible association with the natural history and severity of the infection [26].
###end p 10
###begin p 11
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 371 373 371 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S </italic>
###xml 500 502 500 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S </italic>
###xml 24 27 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 275 278 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 381 384 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
In Mexico, frequency of HBV chronic carriers is low, and the prevalence of HBsAg in blood donors ranges from 0.15 to 1.4% [27,28]; the frequency of hepatocellular carcinoma is also low [29]. Scarce studies have addressed genetic diversity and amino acids changes in HBsAg of HBV strains from Mexico [30]. The aim of the present work was to study genetic diversity in the S gene of HBV strains from asymptomatic and symptomatic carriers in Mexico. Genotype and mutations in the "a" determinant of the S gene leading to amino acids changes were compared between these two groups.
###end p 11
###begin title 12
Results
###end title 12
###begin p 13
###xml 149 151 149 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 293 295 293 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 681 682 681 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 822 823 822 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1624 1625 1624 1625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 45 50 <span type="species:ncbi:9606">women</span>
###xml 82 85 <span type="species:ncbi:9606">men</span>
###xml 181 189 <span type="species:ncbi:9606">patients</span>
###xml 193 198 <span type="species:ncbi:9606">women</span>
###xml 229 232 <span type="species:ncbi:9606">men</span>
###xml 629 637 <span type="species:ncbi:9606">patients</span>
###xml 1222 1225 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 1482 1490 <span type="species:ncbi:9606">patients</span>
We studied 21 asymptomatic HBsAg carriers, 3 women (mean age 30 years old) and 18 men (mean age 42 years old), with average viral load of 0.7965 x 104 copies/ml; and 12 symptomatic patients, 5 women (mean age 50 years old) and 7 men (mean age 39 years old), with average viral load of 2.7 x 106 copies/mL (Table 1). Functional hepatic tests confirmed hepatic damage in symptomatic but not in asymptomatic cases (Table 1). Genotypes were determined by reverse hybridization and sequencing. Genotypes determined by reverse hybridization were H, C, F, C/H, C/F/H and indeterminate (ID) in asymptomatic cases, whereas in symptomatic patients only H and C/H genotypes were found (Table 2). On the other hand, the genotypes determined with the sequencing technique were only H, and C; genotype H was the predominant type (Table 2). In four asymptomatic cases the genotype could not be determined (ID) with the reverse hybridization technique, but was identified as genotype H with the sequencing method. Sequences of the "a" determinant were aligned with sequences of genotypes A-H (Z72478, X98077, AB048704, AB048701, AB032431, AB036907, AF160501, U91827, NC_003977) and analyzed to identify mutations. Mutations identified in HBV strains from the asymptomatic group were Y100N, T126I, Q129H and N146K; whereas in strains from the symptomatic group identified mutations were F93I and A128V. Subtypes found in the asymptomatic group were adw4q+, adw1q+, and adrq+; whereas in symptomatic patients subtypes detected where only adw4q+, and adrq+. Altogether, the genotype/subtype most frequent in our population was H/adw4q+ (Table 2).
###end p 13
###begin p 14
###xml 0 3 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
HBV viral load and hepatic function tests of asymptomatic and symptomatic carriers.
###end p 14
###begin p 15
###xml 49 52 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Genotypes and subtypes of the "a" determinant of HBV strains from asymptomatic and symptomatic cases, determined by both reverse hybridization and sequencing techniques.
###end p 15
###begin p 16
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 108 111 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
Diversity in the amino acid sequence of the "a" determinant among strains from asymptomatic and symptomatic HBV Mexican carriers is presented in Table 3. T113S, S114T, R122K, I126T and P127L were the most frequent in both asymptomatic and symptomatic patients; whereas A159G, R160K, F161Y and V168A were more frequent in symptomatic patients.
###end p 16
###begin p 17
Frequency of aminoacid variants in the "a" determinant of HBsAg in strains from asymptomatic and symptomatic Mexican carriers.
###end p 17
###begin title 18
Discussion
###end title 18
###begin p 19
###xml 46 49 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
In this work we analyzed genetic diversity in HBV isolates from asymptomatic (blood donors) and symptomatic chronic carriers in Mexico. Genotypes were determined with a commercially available reverse-hybridization technique and compared with the sequencing technique. Reverse hybridization allows the detection of infection with mixed genotypes, suggesting that this technique is more reliable than sequencing to detect quasispecies present in lower proportion in the sample; although in some cases it failed to establish the genotype. On the other hand, besides genotyping, nucleic acid sequencing provides information on nucleotide and amino acid sequences of the region investigated, while other molecular methods detect only the point mutations specified by the probes or primers used.
###end p 19
###begin p 20
###xml 698 700 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 990 992 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
###xml 576 584 <span type="species:ncbi:9606">patients</span>
###xml 628 636 <span type="species:ncbi:9606">patients</span>
###xml 809 812 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 900 903 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Of interest, a higher diversity in the infecting genotypes was found among asymptomatic carriers (H, C, F, C/H, C/F/H), than in symptomatic patients, where genotype H was found in all cases and in only one case a C/H infection was detected. These results would suggest that in our population, genotype H strains are more prevalent than C and F genotypes in symptomatic cases. This observation is relevant since studies indicate certain association of the genotype with the clinical outcome of the infection; thus, in hepatocellular carcinoma, genotype C was more prevalent in patients >50 years and genotype B more prevalent in patients <50 years of age, than in age-matched asymptomatic carriers [37]. Of interest, in our study, genotype C was identified in four of the 21 asymptomatic cases. Alternatively, LMV treatment in the symptomatic cases might be selecting for the H genotype. Diversity of HBV genotypes may also affect the accuracy of diagnostic tests and therapeutic decisions [32].
###end p 20
###begin p 21
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 770 772 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 935 937 935 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S </italic>
###xml 1014 1016 1014 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 0 3 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 363 371 <span type="species:ncbi:9606">patients</span>
###xml 563 577 <span type="species:ncbi:489493">HBV genotype H</span>
HBV has been classified in eight genotypes, A through H [18], which show a geographic distribution. In this study, genotype H was found as the predominant genotype in Mexican strains, followed by genotypes C and F. Genotype H has a close phylogenetic relationship with genotype F [17,18]. The genotype C is reported as prevalent in Asian populations [20,33], and patients observed in our population might correspond to imported cases, due to the increased mobility among Asian and Latin-American countries; in fact, recent reports have documented the presence of HBV genotype H strains among Japanese blood donors [34], as an evidence of the global mobility. The genotype prevalent in a population may determine the type of mutations prevalent in the infecting strains [35]; for example, the immune-escape mutant G145R is closely associated with genotype D [36]. HBsAg has also been classified in subtypes based on the sequence of the S gene and in identification of the amino acids encoded at specific positions [33]; in our population, subtypes, like genotypes, were more diverse among strains from asymptomatic carriers than in symptomatic cases.
###end p 21
###begin p 22
###xml 521 523 521 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 541 543 541 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S </italic>
###xml 833 835 833 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S </italic>
###xml 924 926 924 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S </italic>
###xml 1049 1051 1049 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S </italic>
###xml 1057 1059 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1127 1129 1127 1129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S </italic>
###xml 31 34 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
###xml 188 191 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 345 348 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 404 407 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 757 760 <span type="species:ncbi:12202?0.5">LMV</span>
The hepatic function tests and HBV viral load showed that in our symptomatic patients there was hepatic damage and high viral replication, which suggests that the antiviral treatment with LMV was not working, even thought the drug was administered for at least one year in all cases. It is likely that after a long failed therapy, resistance to LMV has been developed. The main mutations associated with LMV resistance are located at the RT gene in the 204 position (rtM204I/V), which is in the catalytic YMDD motif. The P gene overlaps the S gene and thus mutations selected during antiviral treatment may cause concomitant changes to the overlapping reading frame; in particular altering the C-terminal region of HBsAg. Thus for mutations associated with LMV resistance, the rtM204V change is associated with a I195M change in the S gene (sI195M), while the rtM204I change is associated with three possible changes in the S gene, sW196S, sW196L, or a stop codon. In addition, mutation rtA181T is associated with the stop mutation sW172stop in the S gene [37]. However, in our study, none of these mutations were found in the S gene of the strains from symptomatic cases.
###end p 22
###begin p 23
###xml 38 40 38 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S </italic>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 34 37 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 714 722 <span type="species:ncbi:9606">patients</span>
###xml 987 995 <span type="species:ncbi:9606">patients</span>
There has been several reports on HBV S gene mutants affecting amino acid position 120, 123, 124 126, 129, 131, 141, 144 and 145 of the "a" determinant and preS region. The most relevant mutations seem to be the substitutions of amino acid G145R, K141E and T131I and insertion of 3 amino acids between residues 123 and 124, since they markedly affect the antigenic structure of HBsAg [38]. Mexican strains of the present study showed mutations at the first and second loop of the "a" determinant; although it should be noted that these mutations differed between asymptomatic and symptomatic strains. Thus, in the asymptomatic cases mutations were found at positions 100, 126, 129, and 146, whereas in symptomatic patients mutation were in positions 93 and128; none of the above mutations are reported to affect significantly the antigenic structure of the protein. It should be emphasized that all cases included in the study were selected because they were HBsAg positive and so those patients with mutations rendering the S protein undetectable with the antibodies tested, were excluded.
###end p 23
###begin title 24
Conclusion
###end title 24
###begin p 25
###xml 88 96 <span type="species:ncbi:9606">patients</span>
###xml 193 196 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 257 265 <span type="species:ncbi:9606">patients</span>
###xml 270 273 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 475 478 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
In conclusion, we report the genotypes of HVB prevalent in symptomatic and asymptomatic patients in Mexico and show that there is more genetic diversity and mutations in the "a" determinant of HBV strains infecting asymptomatic carriers than in symptomatic patients. In HBV strains from our population genotype H and subtype adw4q+ were predominant. The role of viral genotype and subtype, as well as the ethnicity of the host in the determination of the clinical outcome of HBV infection is still unclear, and studies on genotypes infecting populations should help to clarify this issue.
###end p 25
###begin title 26
Methods
###end title 26
###begin title 27
Serum and plasma samples
###end title 27
###begin p 28
###xml 201 209 <span type="species:ncbi:9606">patients</span>
###xml 308 316 <span type="species:ncbi:9606">patients</span>
###xml 422 425 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 563 575 <span type="species:ncbi:9606">participants</span>
Blood samples were drawn from 21 asymptomatic blood donors, at the Central Blood Bank, Centro Medico Nacional-Siglo XXI (CMN-SXXI), Instituto Mexicano del Seguro Social (IMSS), and from 12 symptomatic patients attending the Hepatitis Clinic, Gastroenterology Service, General Hospital, CMN-SXXI-IMSS. All 33 patients were selected because they were known to be HBsAg carriers. Symptomatic cases were receiving lamivudine (LMV) treatment during at least one year. The study was approved by the IRB Committee of IMSS. Informed consent was obtained from all studied participants.
###end p 28
###begin title 29
Serology
###end title 29
###begin p 30
###xml 257 261 257 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
Assay for HBsAg was performed in sera using a commercial HBsAg test (version 2 IMx, Abbott Laboratories, IL, USA) following manufacturer's instructions. Hepatic function tests (ALT, AST, Billirubins) were performed using the commercially available Dimension(R) Clinical Chemistry System (Dade Behring, Inc. Neward, DE, USA).
###end p 30
###begin title 31
Viral load
###end title 31
###begin p 32
###xml 0 3 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 93 96 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
HBV viral load was determined in plasma with a commercial quantitative assay (COBAS AMPLICOR HBV Monitortrade mark, Roche Diagnostics, Indianapolis, IN, USA) according to manufacturer's instructions.
###end p 32
###begin title 33
DNA extraction
###end title 33
###begin p 34
###xml 55 59 55 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 68 72 66 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 0 3 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
HBV DNA was extracted from plasma specimens with QIAamp(R) Ultrasens(R) Virus kit (QIAGEN) following manufacturer's instructions.
###end p 34
###begin title 35
PCR amplification of the S gene
###end title 35
###begin p 36
###xml 18 20 18 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S </italic>
###xml 619 620 617 618 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 659 663 657 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 994 996 966 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
A fragment of the S gene was amplified by nested PCR. Sequences of the primers and their relative positions were as follows: outer primers included HBV1-sense, 5'-CGC TGG ATG TGT CTG CGGCGT-3', position 371-391, and HBV2-antisense, 5'-CGA ACC ACT GAA CAA ATG GCA CT-3', position 682-704; inner primers were HBV3-sense, 5'-CAT CCT GCT GCT ATG CCT CAT CT-3', position 409-431 and HBV4-antisense, 5'-GGC ACT AGT AAA CTG AGC CA-3', position 668-687 (30). Ten muL of DNA extracted from plasma (template) were mixed with 40 muL of reaction mixture containing 1x PCR Buffer, 50 pmoles of each primer, 0.8 mM dNTPs, 2.5 mM MgCl2, and 2.5 U Taq polymerase (Amplificasa(R) BIOGENICA, Mexico City, Mexico). Annealing and elongation for both primer pairs was for 90 sec at 47degreesC and 72degreesC, respectively. The first PCR was carried out for 45 cycles and the nested PCR for 40 cycles, using an initial denaturing step of 95degreesC for 2 min and a final amplification step of 72degreesC for 15 min [39].
###end p 36
###begin title 37
Sequencing
###end title 37
###begin p 38
###xml 132 136 132 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
PCR products (279 bp) were run in 2% agarose gel electrophoresis and the isolated band was extracted with a commercial kit (QIAquick(R) Gel Extraction Kit, QIAGEN). The purified product was used for sequencing with the chain termination method, using Big Dye Terminator version 3.1 (ABI PRISMtrade mark, Foster City, CA, USA). Extension products were purified (DyeExtrade mark 2.0 Kit, QIAGEN) and separated in an automated DNA genetic analyzer (377 ABI PRISMtrade mark).
###end p 38
###begin title 39
Sequence analysis
###end title 39
###begin p 40
Alignment of sequences was done using the Mega 3.1 program and analyzed manually by visual inspection.
###end p 40
###begin title 41
Genotyping
###end title 41
###begin p 42
###xml 85 88 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Genotyping was carried out in DNA extracted from plasma samples, using the INNO-LiPA HBV amplification and genotyping tests (Innogenetics, Ghent Belgium), following manufacturer's instructions.
###end p 42
###begin title 43
NCBI genotyping system
###end title 43
###begin p 44
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 78 81 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Genotype was also determined by sequence analysis of the 279 bp fragment from HBV "a" determinant, using the genotyping tool available at the National Library of Medicine's National Center for Biotechnology Information (NCBI) [40] using BLAST with a set of reference sequences with known genotypes [41].
###end p 44
###begin title 45
Competing interests
###end title 45
###begin p 46
The authors declare that they have no competing interests.
###end p 46
###begin title 47
Authors' contributions
###end title 47
###begin p 48
MERT: Designed and supervised most of the molecular studies; analyzed sequences and interpreted results. Participated in the preparation of the manuscript.
###end p 48
###begin p 49
HAVS: carried out molecular techniques and participated in the analysis of results.
###end p 49
###begin p 50
VJB: carried out immunoassays and interpreted the results.
###end p 50
###begin p 51
###xml 85 93 <span type="species:ncbi:9606">patients</span>
MDV: responsible for the clinical aspects of the study, including the recruitment of patients; participated in the writing of the manuscript.
###end p 51
###begin p 52
JT: Participated in the designed of the study and in the analyses and interpretation of the results. Critical review and edition of the manuscript.
###end p 52
###begin p 53
OMH: Participated in the clinical designed of the study and in obtaining financial support for the study.
###end p 53
###begin p 54
MTAM: responsible for the design of the study and for acquiring financial support. Supervision of the experimental work. Participated in the drafting of the manuscript.
###end p 54
###begin title 55
Acknowledgements
###end title 55
###begin p 56
This work was supported by the Instituto Mexicano del Seguro Social (IMSS), Coordinacion de Investigacion en Salud (grant FP2003-040). The authors are grateful to Juan Burgueno-Ferreira, Ph.D. for statistical analysis; Othon Rojas-Montes, Mario Valle-Aguirre, Ma.-Carmen Real-Rosas for technical support.
###end p 56
###begin article-title 57
###xml 4 21 <span type="species:ncbi:10407">hepatitis B virus</span>
The hepatitis B virus
###end article-title 57
###begin article-title 58
Characterization of anti-hepatitis B surface antigen monoclonal antibodies
###end article-title 58
###begin article-title 59
Hepatitis B surface antigen variation and protective immunity
###end article-title 59
###begin article-title 60
Immunologic aspects of acute and chronic hepatitis B and C
###end article-title 60
###begin article-title 61
###xml 24 41 <span type="species:ncbi:10407">Hepatitis B virus</span>
###xml 45 52 <span type="species:ncbi:9606">infants</span>
Surface gene mutants of Hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis
###end article-title 61
###begin article-title 62
###xml 52 60 <span type="species:ncbi:9606">children</span>
Molecular analysis of the a determinant of HBsAg in children of HBeAg-positive mothers upon failure of postexposure prophylaxis
###end article-title 62
###begin article-title 63
High affinity monoclonal antibodies to hepatitis B surface antigen(HBsAg) produced by somatic cell hybrids
###end article-title 63
###begin article-title 64
Immune response to synthetic peptide analogues of Hepatitis B surface antigen specific for the a determinant
###end article-title 64
###begin article-title 65
A topological model for Hepatitis B surface antigen
###end article-title 65
###begin article-title 66
###xml 46 63 <span type="species:ncbi:10407">Hepatitis B virus</span>
The prevalence of surface antigen variants of Hepatitis B virus in Papua, New Guinea, South Africa and Sardinia
###end article-title 66
###begin article-title 67
###xml 46 52 <span type="species:ncbi:10090">murine</span>
Characterization of the reactivity pattern of murine monoclonal antibodies against wild type hepatitis B surface antigen to G145R and other naturally occurring "a" loop escape mutations
###end article-title 67
###begin article-title 68
###xml 26 43 <span type="species:ncbi:10407">hepatitis B virus</span>
Altered antigenicities of hepatitis B virus surface antigen carrying mutations outside the common "a" determinant
###end article-title 68
###begin article-title 69
###xml 60 77 <span type="species:ncbi:10407">hepatitis B virus</span>
The clinical significance of molecular variation within the hepatitis B virus genome
###end article-title 69
###begin article-title 70
###xml 45 62 <span type="species:ncbi:10407">hepatitis B virus</span>
Sequential changes in full-length genomes of hepatitis B virus accompanying acute exacerbation of chronic hepatitis B
###end article-title 70
###begin article-title 71
###xml 64 81 <span type="species:ncbi:10407">hepatitis B virus</span>
High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum
###end article-title 71
###begin article-title 72
###xml 89 106 <span type="species:ncbi:10407">hepatitis B virus</span>
Complete genomes, phylogenetic relatedness and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes
###end article-title 72
###begin article-title 73
###xml 18 35 <span type="species:ncbi:10407">hepatitis B virus</span>
A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness
###end article-title 73
###begin article-title 74
###xml 41 58 <span type="species:ncbi:10407">hepatitis B virus</span>
Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America
###end article-title 74
###begin article-title 75
###xml 145 162 <span type="species:ncbi:10407">hepatitis B virus</span>
Comparison of the aminoacid sequences of nine different serotypes of Hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains
###end article-title 75
###begin article-title 76
Genetic relatedness of Hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen
###end article-title 76
###begin article-title 77
###xml 7 24 <span type="species:ncbi:10407">hepatitis B virus</span>
Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes
###end article-title 77
###begin article-title 78
###xml 23 26 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Genotype F prevails in HBV infected patients of hispanic origin in Central America and may carry the precore stop mutant
###end article-title 78
###begin article-title 79
###xml 26 43 <span type="species:ncbi:10407">hepatitis B virus</span>
Molecular epidemiology of hepatitis B virus in Central America reflected in the genetic variability of the small S gene
###end article-title 79
###begin article-title 80
###xml 24 41 <span type="species:ncbi:10407">hepatitis B virus</span>
A unique segment of the hepatitis B virus group A genotype identified in isolates from South Africa
###end article-title 80
###begin article-title 81
###xml 35 52 <span type="species:ncbi:10407">hepatitis B virus</span>
Increased prevalence of genotype F hepatitis B virus isolates in Buenos Aires, Argentina
###end article-title 81
###begin article-title 82
###xml 35 38 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Advances in molecular diagnosis of HBV infection and drug resistance
###end article-title 82
###begin article-title 83
Hepatitis B and delta: the prevalence of seroepidemiological markers in volunteer blood donors and their families
###end article-title 83
###begin article-title 84
Hepatitis B epidemiology in Latin America
###end article-title 84
###begin article-title 85
Hepatocellular carcinoma is rarely present in Western Mexico
###end article-title 85
###begin article-title 86
###xml 43 60 <span type="species:ncbi:10407">hepatitis B virus</span>
Genotype and S-gene variability of Mexican hepatitis B virus strains
###end article-title 86
###begin article-title 87
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Hepatitis B genotypes correlate with clinical outcome in patients with chronic hepatitis B
###end article-title 87
###begin article-title 88
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus genotypes:comparison of genotyping methods
###end article-title 88
###begin article-title 89
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus genetic diversity
###end article-title 89
###begin article-title 90
###xml 65 82 <span type="species:ncbi:10407">hepatitis B virus</span>
JRC NAT Screening Research Group. Characterization of genotype H hepatitis B virus identified for the first time from a Japanese blood by nucleic acid amplification test
###end article-title 90
###begin article-title 91
Molecular epidemiology of hepatitis B in Latin America
###end article-title 91
###begin article-title 92
###xml 57 74 <span type="species:ncbi:10407">hepatitis B virus</span>
The clinical significance of surface antigen variants of hepatitis B virus
###end article-title 92
###begin article-title 93
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus mutations associated with antiviral therapy
###end article-title 93
###begin article-title 94
Effect of variation in the common "a" determinant on the antigenicity of hepatitis B surface antigen
###end article-title 94
###begin article-title 95
###xml 69 76 <span type="species:ncbi:9606">infants</span>
###xml 90 107 <span type="species:ncbi:10407">hepatitis B virus</span>
Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection
###end article-title 95
###begin article-title 96
Genotyping Tool
###end article-title 96
###begin article-title 97
A web-based genotyping resource for viral sequences
###end article-title 97

